News | September 10, 2025
Navin Fluorine inaugurates Phase-1 of new cGMP-4 facility of Navin Molecular at Devas
The cGMP-4 facility will further strengthen the company's ability to serve global partners
The cGMP-4 facility will further strengthen the company's ability to serve global partners
The facility has been designed with a dual focus on efficiency and sustainability
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
The company has received approval from DCGI to begin patient enrolment and dosing in the country
PendraCare Group develops, manufactures and sells innovative cardiology catheter solutions and provides design, development and manufacturing services to other global OEM’s
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
Subscribe To Our Newsletter & Stay Updated
